Market Research Logo

Parkinson's Disease Global Clinical Trials Review, H1, 2018

Parkinson's Disease Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Parkinson's Disease Global Clinical Trials Review, H1, 2018 provides an overview of Parkinson's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Parkinson's Disease Therapeutics, Global, Clinical Trials by Region (%), 2018*
    • Table Parkinson's Disease Therapeutics, Global, Clinical Trials by Region, 2018*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Figure 3: Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Table Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
        • Table Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
        • Table Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
        • Table Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
        • Table Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
        • Table Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials
    • Table Figure 9: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
    • Table Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
    • Table Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials
    • Table Figure 12: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
    • Table Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
    • Table Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by Phase
    • Table Figure 15: Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2018*
    • Table Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase, 2018*
    • In Progress Trials by Phase
      • Table Figure 16: Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
      • Table Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Clinical Trials by Trial Status
    • Table Figure 17: Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2018*
    • Table Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by End Point Status
    • Table Figure 18: Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2018*
    • Table Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
    • Table Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
    • Table Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Prominent Sponsors
    • Table Figure 21: Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Table Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials
      • Table Figure 22: Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
      • Table Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Prominent Drugs
    • Table Figure 23: Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
    • Table Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Latest Clinical Trials News on Parkinson's Disease
    • Apr 30, 2018: Elto PharmaAppoints Paula Trzepacz, MD as Chief Medical Advisor
    • Apr 26, 2018: Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting
    • Apr 24, 2018: Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
    • Apr 19, 2018: Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinson's Disease Patients with Dyskinesia
    • Apr 18, 2018: Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson's Disease Presentations at American Academy of Neurology Annual Meeting
    • Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome
    • Apr 12, 2018: Adamas Announces Data Presentations on GOCOVRI at The American Academy Of Neurology Annual Meeting
    • Apr 12, 2018: Bumetanide strikes again in the arena of neurological disorders: a novel therapeutic approach to treat Parkinson's disease
    • Apr 10, 2018: Approval For Rotigotine Extended Release Microspheres For Injection From Phase III Clinical Trials In China
    • Apr 04, 2018: Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting
    • Apr 03, 2018: Intec Pharma to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease
    • Mar 29, 2018: Herantis Pharma publishes an introductory video on its drug candidate CDNF for the treatment of Parkinson's disease
    • Mar 26, 2018: Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment
    • Mar 15, 2018: Biogen to Present at the 2018 Advances in Alzheimer's and Parkinson's Therapies (AATAD/ PD) Focus Meeting
    • Mar 15, 2018: Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
    • Mar 15, 2018: Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinson Disease Patients with Dyskinesia
    • Mar 09, 2018: Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VYAADC for Advanced Parkinson's Disease
    • Mar 05, 2018: International Stem Cell Completes Dosing Of Second Cohort In Parkinson's Disease Clinical Trial
    • Feb 27, 2018: Hisamitsu Pharmaceutical Announces the Results of Phase III Clinical Study of HP-3000 in Japan
    • Feb 26, 2018: Cantabio Pharmaceuticals to Present Results from its Tau Protein Targeting Therapeutic Program for the treatment of Alzheimer Disease at the Advances in Alzheimer and Parkinson Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy
    • Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
    • Feb 08, 2018: Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
    • Feb 08, 2018: Rotigotine Extended Release Microspheres For Injection Exempted From Phase II Clinical Trials in the United States
    • Feb 06, 2018: First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson's Disease
    • Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline - IRL752
    • Jan 31, 2018: IRLAB Provides Update On Clinical Phase II pipeline - IRL790
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report